Mind Medicine (MindMed) Inc., a late-stage clinical biopharmaceutical company, has announced the issuance of inducement grants to six newly hired non-executive employees. These grants consist of options to purchase a total of 96,400 common shares, with effective grant dates slated for July 7 and July 14, 2025, based on each employee's start date. The options, which carry an exercise price equal to the closing price of MindMed's common shares on their respective grant dates, will vest over a four-year period. Initial vesting of 25% will occur on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly increments over the subsequent three years, contingent upon continued employment. The grants were approved by MindMed's Compensation Committee and issued outside of the company's equity incentive plans, in line with NASDAQ's Rule 5635(c)(4).